21st-23rd May 2019

Boston, USA

Register Interest 

2018 Workshops

Web Logos

Workshop A Workshop B

Post-Conference Workshop Day

Wednesday February 28, 9:00 am-12:00 pm

WORKSHOP A

Generating Designer Animal Models Using Easi-CRISPR

(This session is separately bookable)

09:00 am -12:00 pm  Workshop Leader

Designing the designer animal models using CRISPR genome editing system In this workshop you will discover:

■ Newer technical breakthroughs in transgenic technologies that have been possible because of the CRISPR/Cas9 system

■ Designing common and advanced type of designer animal models for basic, translational and pharmaceutical research

■ Case studies: evaluation of animal model designs of participants’ examples

Guru Channabasavaiah

Guru Channabasavaiah, Director, UNMC

CB Gurumurthy is an Associate Professor of Developmental Neuroscience, Munroe Meyer Institute for Genetics and Rehabilitation, and he serves as the Director of UNMC Mouse Genome Engineering Core Facility at the University of Nebraska Medical Center. He received his BVSC (DVM) from Bangalore Veterinary College, India and MVSC & PHD in Veterinary Virology from Indian Veterinary Research Institute with a Gold Medal distinction in MVSC. Prior to his current position, he served as a Molecular Biology Scientist, Drug Discovery Research at Dr. Reddy’s Laboratories, and then he moved to Northwestern University, Chicago for a Post-Doctoral work in Cancer Biology and Mouse Molecular Genetics. He also received his Executive MBA from University of Nebraska at Omaha. His research interests are improving and development of novel genome engineering technologies.

 

Parte 8

 

Wednesday February 28, 1:00 pm-4:00 pm

WORKSHOP B

Future Safety and Efficacy: Exploring the Alignment of CRISPR and the Future of Therapeutic Development to the Future of Clinical
Trial Design

(This session is separately bookable)

1:00 pm-4:00 pm  Workshop Leader

This workshop will enable you to:

■ Discuss how drug development and regulatory processes need to continue to embrace data science technology to enhance clinical trial efficiency for therapeutics using CRISPR as well as other innovations

■ Explore the history of the Virtual Subject model for Clinical Trial development and execution

■ Address opportunities, considerations, and best practices to drive toward the frontier of executing trials with virtual subjects

8931 - Dan Tierno

Dan Tierno,Strategic Implementation Manager, Bayer

Mr. Dan Tierno has over 20 years of experience in portfolio management, drug development, mHealth, clinical trial design, cell and gene therapy and gene editing. Mr. Tierno has spoken on training scientists for rare disease therapeutic development, innovations in drug development and clinical trials, commercialization of cell therapies, gene therapies and gene editing therapies. Mr. Tierno also has spoken on the topic of defining and generating value via portfolio management. Mr. Tierno holds his Honors M.B.A. from the Zicklin School of Business at Baruch College, and his M.A. in Biotechnology from Columbia University. In his spare time coaches youth recreation sports, runs a community garden that has donated over 200lbs. of fresh vegetables to local soup kitchens, as well as plays recreation softball and soccer. He lives in Metuchen N.J. with his wife Nicole and son Devin (7) and daughter Liliana (4).